MedTrace Logo

Treatment of Latent Tuberculosis Infection With Isoniazid

NCT00293228 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2010-05-26

No results posted yet for this study

Summary

The purpose of this study is to study the effect that treatment of dormant tuberculosis infection has on the immunological system.

We expect to observe an impact over the production of cytokines by peripheral white blood cells which may be useful to know if treatment has been effective.

Conditions

Interventions

DRUG

Isoniazid

Isoniazid (5mg per kg up to 300 mg daily for 6 months)

DRUG

isoniazid

isoniazid (5mg per kg up to 300 mg daily for 6 months

Sponsors & Collaborators

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • Wellcome Trust

    collaborator OTHER

  • Instituto Nacional de Salud Publica, Mexico

    lead OTHER

Principal Investigators

  • Lourdes Garcia-Garcia, MD · Instituto Nacional de Salud Pública

  • Jose Sifuentes-Osornio, MD · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

  • Alfredo Ponce-de-Leon, MD · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran

  • Eduardo Sada-Diaz, MD · Instituto Nacional de Enfermedades Respiratorias

  • Martha Torres-Rojas, MD · Instituto Nacional de Enfermedades Respiratorias

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-03-31
Completion
2009-06-30

Countries

  • Mexico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00293228 on ClinicalTrials.gov